Annette Eidam

ORCID: 0000-0002-1490-9456
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Nutrition and Health in Aging
  • Frailty in Older Adults
  • Health Systems, Economic Evaluations, Quality of Life
  • Pharmaceutical Practices and Patient Outcomes
  • Intensive Care Unit Cognitive Disorders
  • Hepatitis B Virus Studies
  • Schizophrenia research and treatment
  • Chronic Disease Management Strategies
  • Maternal Mental Health During Pregnancy and Postpartum
  • HIV/AIDS drug development and treatment
  • Hepatitis C virus research
  • Cancer survivorship and care
  • Sepsis Diagnosis and Treatment
  • Electrolyte and hormonal disorders
  • Diabetes Treatment and Management
  • Nutritional Studies and Diet
  • Pregnancy and Medication Impact
  • Pharmaceutical Economics and Policy
  • Cerebral Palsy and Movement Disorders
  • Dementia and Cognitive Impairment Research
  • Drug Transport and Resistance Mechanisms
  • Medication Adherence and Compliance
  • Pharmaceutical studies and practices
  • Obesity, Physical Activity, Diet
  • Lipoproteins and Cardiovascular Health

University Hospital Heidelberg
2016-2024

Heidelberg University
2016-2024

Agaplesion Bethanien Krankenhaus
2019-2024

Ministry of Science
2019

Engineering Arts (United States)
2019

Agaplesion Bethesda Klinik
2019

Quality of Life Research Center
2019

German Center for Infection Research
2017

Myrcludex B acts as a hepatitis and D virus entry inhibitor blocking the sodium taurocholate cotransporting polypeptide (SLC10A1). We investigated effects of myrcludex on plasma bile acid disposition, tenofovir pharmacokinetics, perpetrator characteristics cytochrome P450 (CYP) 3A. Twelve healthy volunteers received 300 mg disoproxil fumarate orally 10 subcutaneous B. increased total exposure 19.2‐fold without signs cholestasis. The rise in conjugated acids was up to 124‐fold (taurocholic...

10.1002/cpt.744 article EN Clinical Pharmacology & Therapeutics 2017-05-25

Abstract Inappropriate polypharmacy is highly prevalent among older adults and presents a significant healthcare concern. Conducting medication reviews implementing deprescribing strategies in multimorbid with are an inherently complex challenging task. Recognizing this, the Special Interest Group on Pharmacology of European Geriatric Medicine Society has compiled evidence review formulated recommendations to enhance appropriate prescribing practices. The current supports need for...

10.1007/s41999-023-00872-0 article EN cc-by European Geriatric Medicine 2023-10-09

10.1007/s00391-021-01873-z article DE Zeitschrift für Gerontologie und Geriatrie 2021-03-29

Anorexia of aging is characterized by an age-associated reduction appetite, whose aetiology in most cases multifactorial and which often triggers malnutrition. The Simplified Nutritional Appetite Questionnaire (SNAQ) established screening tool. This study aimed to investigate reliability, validity, feasibility its telephone administration (T-SNAQ) German community-dwelling older adults.This cross-sectional single-centre recruited participants from April 2021 September 2021. First, the SNAQ...

10.1002/jcsm.13264 article EN cc-by Journal of Cachexia Sarcopenia and Muscle 2023-05-22

Adverse anticholinergic drug reactions are common, yet evidence on how to reduce exposure activity and reliably measure successful deprescribing is still scant. This study proposes an algorithm-based approach evaluate load, reports the results of its pilot testing. Based published expert opinion, a list 85 drugs 21 algorithms for reducing e.g., by recommending alternative with lower risk, were developed. An accompanying test battery was assembled focusing instruments that sensitively reflect...

10.1007/s40266-023-01089-3 article EN cc-by-nc Drugs & Aging 2024-02-01

There is increasing research interest in cholesterol-lowering therapy older patients. The newer lipid-lowering agents (the proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitors evolocumab and alirocumab; the PCSK9 synthesis inhibitor inclisiran, adenosine triphosphate–citrate lyase bempedoic acid) might also provide more options for future treatment of Data analyses phase III outcome trials suggest that their clinical benefits are maintained at ages there no increased relative...

10.1007/s40266-022-00928-z article EN cc-by-nc Drugs & Aging 2022-03-12

Frailty makes older adults vulnerable to adverse health outcomes and can modify pharmacokinetics drug exposure. We aimed explore the relationship between different frailty assessments trough plasma concentrations of direct oral anticoagulants in patients. The status aged ≥ 70 years receiving regular anticoagulant medication was assessed by four instruments: Fried physical phenotype, Rockwood index, Short Physical Performance Battery, FRAIL scale. two performance measures "slow gait speed"...

10.1007/s40266-022-00999-y article EN cc-by-nc Drugs & Aging 2023-01-13

Frailty führt bei älteren Erwachsenen zu einer erhöhten Vulnerabilität für negative Gesundheitsereignisse. Bislang existiert kein Goldstandard zur Diagnose Frailty. Dieser Beitrag bietet einen Überblick über die wichtigsten Instrumente Frailty-Diagnostik und ihre Anwendungsbereiche.

10.1055/a-2033-4957 article DE DMW - Deutsche Medizinische Wochenschrift 2023-12-29

Frailty beschreibt als ein übergeordnetes geriatrisches Syndrom potenziell reversibles Übergangsstadium zwischen funktioneller Autonomie und irreversibler Hilfsbedürftigkeit. adressiert damit "Window of Opportunity", in dem funktionelle Einschränkungen mit Erfolg therapiert werden können. Der vorliegende Beitrag gibt einen Überblick über aktuelle Therapieansätze ihre wissenschaftliche Evidenz.

10.1055/a-2033-5001 article DE DMW - Deutsche Medizinische Wochenschrift 2023-12-29

Medical decision-making in older adults with multiple chronic conditions and polypharmacy should include the individual patient's treatment preferences. We developed pilot-tested an electronic instrument (PolyPref) to elicit patient preferences geriatric polypharmacy.PolyPref follows a two-stage direct approach preference assessment. Stage 1 generates preselection of relevant health outcomes medication regimen characteristics, followed by stage 2, which their importance is assessed using...

10.2147/ppa.s364681 article EN cc-by-nc Patient Preference and Adherence 2022-07-01
Coming Soon ...